BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 15, Issue 2
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (6501)
All Articles published online
The chart showing PDF series, WORD series, HTML series.
Item 
Count 
PDF154
WORD19
HTML3910
 Sum=4083
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse443
Download821
 Sum=1264
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse227
Download659
 Sum=886
Feb 15, 2024 (publication date) through Oct 24, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Nassar M, Chaudhuri A, Ghanim H, Dandona P. Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon. World J Diabetes 2024; 15(2): 133-136 [PMID: 38464377 DOI: 10.4239/wjd.v15.i2.133]
URL: https://www.wjgnet.com/1948-9358/full/v15/i2/133.htm
Number Citing Articles
1
Sujatha Seetharaman, Eda Cengiz. The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists. Journal of Diabetes Science and Technology 2025; 19(2): 311 doi: 10.1177/19322968241309896
2
Xiao Yang, Xinghui Li. Research Progress on the Association Between GLP-1 Receptor Agonists and Cardiomyopathy. Reviews in Cardiovascular Medicine 2025; 26(8) doi: 10.31083/RCM37180
3
Marco Infante, Francesca Silvestri, Nathalia Padilla, Francesca Pacifici, Donatella Pastore, Marcelo Maia Pinheiro, Massimiliano Caprio, Manfredi Tesauro, Andrea Fabbri, Giuseppe Novelli, Rodolfo Alejandro, Antonino De Lorenzo, Camillo Ricordi, David Della-Morte. Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults. Journal of Clinical Medicine 2025; 14(4): 1303 doi: 10.3390/jcm14041303
4
Hyder O Mirghani. Glucagon-like peptide-1 agonists: Role of the gut in hypoglycemia unawareness, and the rationale in type 1 diabetes. World Journal of Diabetes 2024; 15(11): 2167-2172 doi: 10.4239/wjd.v15.i11.2167
5
Mahmoud Nassar, Angad Singh Gill, Erlin Marte. Investigating the impact of intestinal glucagon-like peptide-1 on hypoglycemia in type 1 diabetes. World Journal of Diabetes 2025; 16(3): 99142 doi: 10.4239/wjd.v16.i3.99142
6
Giuseppe Lisco, Anna De Tullio, Olga Eugenia Disoteo, Michela Armigliato, Edoardo Guastamacchia, Simonetta Marucci, Giovanni De Pergola, Enrico Papini, Marco Chianelli, Andrea Frasoldati, Vincenzo De Geronimo, Vincenzo Triggiani. Incretin‐Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists. Diabetes/Metabolism Research and Reviews 2025; 41(6) doi: 10.1002/dmrr.70073
7
Mahmoud Nassar, Omar Nassar, Hazem Abosheaishaa, Anoop Misra. Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2024; 18(9): 103116 doi: 10.1016/j.dsx.2024.103116
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345